Barclays analyst Carter Gould raised the firm’s price target on Gilead (GILD) to $95 from $84 and keeps an Equal Weight rating on the shares. The company delivered a Q3 beat and raise, helped by Veklury but also Biktarvy, the analyst tells investors in a research note.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences Shows Strong Q3 Results Amid Strategic Initiatives
- Closing Bell Movers: AppLoving up 29% after Q3 earnings beat
- Gilead reports Q3 adjusted EPS $2.02, consensus $1.55
- Gilead raises FY24 EPS view to $4.25-$4.45 from $3.60-$3.90, consensus $3.81
- Notable companies reporting after market close